Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Baudax Bio, Inc.    BXRX

BAUDAX BIO, INC.

(BXRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Baudax Bio : to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

share with twitter share with LinkedIn share with facebook
09/18/2020 | 07:36am EDT

MALVERN, Pa., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Tuesday, September 22, 2020 at 3:20 p.m. ET.

A live webcast of the presentation will be available on the “Presentations” page within the Investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of the Company’s first commercial product, ANJESO®, began in June of 2020. Baudax’s New Drug Application for ANJESO was approved by FDA on February 20, 2020 for the management the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. As a non-opioid, IV meloxicam has the potential to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, as well as having no addictive potential while maintaining meaningful analgesic effects for relief of pain. For more information please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
sam@argotpartners.com
claudia@argotpartners.com

Baudax Bio, Inc.
Ryan D. Lake
(484) 395-2436
rlake@baudaxbio.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com


baudax bio.jpg

Source: Baudax Bio, Inc.

2020 GlobeNewswire, Inc., source Press Releases


share with twitter share with LinkedIn share with facebook
All news about BAUDAX BIO, INC.
10/02BAUDAX BIO : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
10/02Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
09/22BAUDAX BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/18BAUDAX BIO : to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech S..
AQ
09/18Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech ..
GL
08/25Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO®
GL
08/21BAUDAX BIO, INC. : Entry into a Material Definitive Agreement, Change in Directo..
AQ
08/20BAUDAX BIO : Appoints Arnold Baskies, M.D. and Andrew Drechsler to Board of Dire..
AQ
08/10BAUDAX BIO : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/10Baudax Bio Reports Second Quarter 2020 Financial Results
GL
More news
Financials (USD)
Sales 2020 4,47 M - -
Net income 2020 -97,0 M - -
Net cash 2020 32,0 M - -
P/E ratio 2020 -0,43x
Yield 2020 -
Capitalization 48,5 M 48,5 M -
EV / Sales 2020 3,70x
Capi. / Sales 2021 1,74x
Nbr of Employees 24
Free-Float 98,4%
Chart BAUDAX BIO, INC.
Duration : Period :
Baudax Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUDAX BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,67 $
Last Close Price 2,64 $
Spread / Highest target 392%
Spread / Average Target 342%
Spread / Lowest Target 317%
EPS Revisions
Managers
NameTitle
Gerri A. Henwood President, Chief Executive Officer & Director
Alfred F. Altomari Chairman
Ryan D. Lake Chief Financial Officer
Stewart Mccallum Chief Medical Officer
William L. Ashton Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUDAX BIO, INC.-61.85%49
LONZA GROUP AG69.31%48 545
SEAGEN INC.73.48%34 961
IQVIA HOLDINGS INC.6.17%31 476
CELLTRION, INC.41.16%30 032
MODERNA, INC.262.78%29 176